Figure 1.
![Treatment of iTTP with the anti-CD38 antibody daratumumab. Clinical course and selected laboratory parameters from hospital admission to the most recent follow-up in 2 patients. Corticosteroids were started at a high dose and then tapered. In patient 2, daily administration of caplacizumab was reduced to every other day after 90 days. (A) Patient 1 with frequently relapsing iTTP; the course of his latest iTTP relapse is shown. (B) Patient 2 with a refractory first iTTP episode. Red line indicates titer of ADAMTS13 inhibitor (Bethesda units [BU] per mL; truncated at 2); blue line indicates ADAMTS13 activity (%); gray line indicates platelet count (× 109/L).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/6/3/10.1182_bloodadvances.2021005124/2/advancesadv2021005124f1.png?Expires=1724949525&Signature=M5K8apzZTEVKiYanIDxyOd-CCjP7VIozL5fSLfOxa6JdZ1PpGxWYbZlzNDF1WujocV4W5oe4jPJlk0Q4R2IUNxHpuNLvPHRLNHDpllwq3u087TdlrFTMqi8Bl2Cs4drH02otl3BI2unaIK-EeZPzDp8zZ619G-m5blZzeZ82YmPltDrUZqGUsdm7~bo6BmBrtjwb6NYFUnJofTl0CK4y-6iFToyRiZp38LfFZ8Mzx08E15VBxy4jghKRZvMV3u-3lpTCAWxm5yLUw9bf1TzRu-GR1OkHNjYyfmpo04rpaw1Ngs-V4yjTash6Xix6q0KPzveLlOGtLh1L6VNxFOawdA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Treatment of iTTP with the anti-CD38 antibody daratumumab. Clinical course and selected laboratory parameters from hospital admission to the most recent follow-up in 2 patients. Corticosteroids were started at a high dose and then tapered. In patient 2, daily administration of caplacizumab was reduced to every other day after 90 days. (A) Patient 1 with frequently relapsing iTTP; the course of his latest iTTP relapse is shown. (B) Patient 2 with a refractory first iTTP episode. Red line indicates titer of ADAMTS13 inhibitor (Bethesda units [BU] per mL; truncated at 2); blue line indicates ADAMTS13 activity (%); gray line indicates platelet count (× 109/L).